| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2013: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Outline of Final Research Achievements |
Advanced glycation endproducts, which readily form and accumulate with sustained hyperglycemia, contribute to the development of diabetic complications and, as such, are considered a potential therapeutic target. Some isolated compounds from two plants showed strong inhibitory activity toward AGEs formation, the inhibitory activity of a positive control, aminoguanidine, being 2.48 mM. The current results ndicate that, in comparison with the reference compound, aminoguanidine, which once entered phase II clinical trials, but was withdrawn because of its side effects, flavonoid glycosides were clearly more efficient in inhibiting the formation of AGEs. Thus, these compounds seem to be worthy of consideration as potential therapeutic agents for diabetic complications and related diseases though additional biological evaluation.
|
